Best of Biosimilars Coverage in 2022
Take a look back at our most popular biosimilars coverage for 2022.
10. Potential Impact of Inflation Reduction Act on Biosimilars
Several provisions in the law are designed to protect and foster the biosimilar market. But some representatives of the sector see CMS drug price negotiation as a threat to profit margins.
9. Discontinuation Rates for Biosimilars Are High But Similar to Rates for Reference Biologics
The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics.
8. Examining What Interchangeable Means in Biosimilars
Some companies are using the interchangeability designation as a marketing ploy.
7. Lowering Patient Drug Costs with Biosimilars Can Happen When the Right Teams Come Together
Pharmacy benefit managers can help health plans understand when to best leverage and align to biosimilars and other cost-effective treatments.
6. Biosimilars for Humira Are on Their Way
Circle 2023 on your calendar. That's when as many as 11 biosimilars to Humira are headed for the US market.
5. Payers Need to Make Effort for Improvements in Biosimilars
Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
4. Biosimilars in Pregnancy
New research should give expectant mothers some peace of mind.
3. Evaluating Pharmacist Attitudes Toward, Understanding of Biosimilars
Gaps exist in knowledge about interchangeability and substitutions.
2. 2022 May Be Turning Point for Biosimilars in US
A new report by Cardinal Health includes research findings on insulin biosimilars use among retail pharmacists and physicians.
1. Efficacy Outcomes of Some Cancer Biosimilars Indistinguishable Vs Reference Product
Findings from a systematic review found little difference in outcomes between biosimilar and reference product treatment options.